JP2020504133A5 - - Google Patents

Download PDF

Info

Publication number
JP2020504133A5
JP2020504133A5 JP2019536560A JP2019536560A JP2020504133A5 JP 2020504133 A5 JP2020504133 A5 JP 2020504133A5 JP 2019536560 A JP2019536560 A JP 2019536560A JP 2019536560 A JP2019536560 A JP 2019536560A JP 2020504133 A5 JP2020504133 A5 JP 2020504133A5
Authority
JP
Japan
Prior art keywords
composition according
antigen
composition
vaccine antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019536560A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020504133A (ja
JP7348063B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/012507 external-priority patent/WO2018129270A1/en
Publication of JP2020504133A publication Critical patent/JP2020504133A/ja
Publication of JP2020504133A5 publication Critical patent/JP2020504133A5/ja
Priority to JP2023145029A priority Critical patent/JP7733703B2/ja
Application granted granted Critical
Publication of JP7348063B2 publication Critical patent/JP7348063B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019536560A 2017-01-05 2018-01-05 ワクチン効力を改善するためのシステム及び方法 Active JP7348063B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023145029A JP7733703B2 (ja) 2017-01-05 2023-09-07 ワクチン効力を改善するためのシステム及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762442903P 2017-01-05 2017-01-05
US62/442,903 2017-01-05
PCT/US2018/012507 WO2018129270A1 (en) 2017-01-05 2018-01-05 Systems and methods to improve vaccine efficacy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023145029A Division JP7733703B2 (ja) 2017-01-05 2023-09-07 ワクチン効力を改善するためのシステム及び方法

Publications (3)

Publication Number Publication Date
JP2020504133A JP2020504133A (ja) 2020-02-06
JP2020504133A5 true JP2020504133A5 (https=) 2021-02-12
JP7348063B2 JP7348063B2 (ja) 2023-09-20

Family

ID=62791369

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536560A Active JP7348063B2 (ja) 2017-01-05 2018-01-05 ワクチン効力を改善するためのシステム及び方法
JP2023145029A Active JP7733703B2 (ja) 2017-01-05 2023-09-07 ワクチン効力を改善するためのシステム及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023145029A Active JP7733703B2 (ja) 2017-01-05 2023-09-07 ワクチン効力を改善するためのシステム及び方法

Country Status (6)

Country Link
US (2) US11566061B2 (https=)
EP (1) EP3565535A4 (https=)
JP (2) JP7348063B2 (https=)
CN (1) CN110121336A (https=)
CA (1) CA3049244A1 (https=)
WO (1) WO2018129270A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP4711465A2 (en) * 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
ES2973548T3 (es) 2016-12-22 2024-06-20 Cue Biopharma Inc Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
US20210299247A1 (en) * 2017-11-01 2021-09-30 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
CN112912391A (zh) * 2018-10-25 2021-06-04 昆士兰医学研究所理事会 T细胞受体及其用途
CA3119188A1 (en) 2018-11-09 2020-05-14 Fred Hutchinson Cancer Research Center T cell receptors specific for mesothelin and their use in immunotherapy
CN109988770B (zh) * 2019-01-10 2022-11-22 中国人民解放军第四军医大学 一种c-di-AMP合成酶单克隆抗体的重链和轻链可变区基因和编码的多肽及其应用
CN111662382A (zh) * 2019-03-06 2020-09-15 瑞阳(苏州)生物科技有限公司 特异结合cd3的抗体、抗原结合片段和单链抗体可变区片段及其应用
WO2020210628A1 (en) * 2019-04-10 2020-10-15 Emv Enhance (Hk) Limited Compositions and methods for improving vaccination of hyporesponsive individuals
WO2020227421A1 (en) 2019-05-09 2020-11-12 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
JP2022532256A (ja) 2019-05-16 2022-07-13 ジェム イノヴ 生分解性マイクロカプセルの調製方法及びこの方法で得たマイクロカプセル
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
WO2021081232A1 (en) * 2019-10-23 2021-04-29 Cue Biopharma, Inc. Modified cytotoxic t cells and methods of use thereof
CN110951797B (zh) * 2019-12-05 2020-08-25 湖北大学 消化链球菌谷氨酸脱氢酶GdhA在提高地衣芽胞杆菌聚γ-谷氨酸产量中的应用
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
CN114106144B (zh) * 2020-08-27 2024-01-26 溧阳瑅赛生物医药有限公司 识别hla-a*02/wt1靶点的tcr及其应用
EP4228658A4 (en) 2020-10-14 2025-02-19 George Mason Research Foundation, Inc. IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
FR3116212B1 (fr) 2020-11-18 2022-12-30 Gem Innov Procede de preparation de microcapsules biodegradables et microcapsules ainsi obtenues
US20240122865A1 (en) * 2021-02-19 2024-04-18 Pfizer Inc. Methods of Protecting RNA
US20240151711A1 (en) * 2021-03-14 2024-05-09 Haifa Shen Adjuvant for vaccine development
CN118843476A (zh) * 2022-01-07 2024-10-25 安达生物药物开发(深圳)有限公司 新型个体化新抗原疫苗和标志物
CN120860194A (zh) * 2025-07-15 2025-10-31 中国人民解放军总医院第一医学中心 一种流感病毒纳米疫苗及其制备方法与应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4078052A (en) 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
CH621479A5 (https=) 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (https=) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6491916B1 (en) 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
US5798100A (en) 1994-07-06 1998-08-25 Immunomedics, Inc. Multi-stage cascade boosting vaccine
US5756122A (en) 1995-06-07 1998-05-26 Georgetown University Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US6242253B1 (en) 1997-10-09 2001-06-05 Regents Of The University Of California IkB kinase, subunits thereof, and methods of using same
CA2395636A1 (en) 1999-12-30 2001-07-12 Novartis Ag Novel colloid synthetic vectors for gene therapy
BR0107972A (pt) * 2000-01-31 2002-11-05 Smithkline Beecham Biologicals Uso de uma proteìna ou polinucleotìdeo tat do hiv, nef do hiv, ou tat do hiv ligado(a) a uma proteìna ou polinucleotìdeo nef do hiv (nef-tat), e de uma proteìna ou polinucleotìdeo gp120 do hiv, método para imunizar um ser humano contra o hiv, e, composição de vacina para o uso humano
US20030072794A1 (en) 2000-06-09 2003-04-17 Teni Boulikas Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes
US7427394B2 (en) 2000-10-10 2008-09-23 Massachusetts Institute Of Technology Biodegradable poly(β-amino esters) and uses thereof
JP2005511761A (ja) 2001-07-10 2005-04-28 ノース・キャロライナ・ステイト・ユニヴァーシティ ナノ粒子送達ビヒクル
US7550650B2 (en) 2001-09-18 2009-06-23 Synageva Biopharma Corp. Production of a transgenic avian by cytoplasmic injection
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US6740336B2 (en) 2002-10-04 2004-05-25 Mirus Corporation Process for generating multilayered particles
CA2501476A1 (en) 2002-10-07 2004-04-22 Chiron Corporation Hiv vaccine formulations
DE602004030923D1 (de) 2003-09-17 2011-02-17 Rodos Biotarget Gmbh Lipid-arzneimittel-formulierungen zur gezielten pharmakotherapie von myeloiden und lymphoiden immunzellen
US7592326B2 (en) * 2004-03-15 2009-09-22 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
ATE417065T1 (de) 2004-05-19 2008-12-15 Medigene Ltd Hochaffiner ny-eso-t-zellen-rezeptor
US8663599B1 (en) 2004-10-05 2014-03-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US7531624B2 (en) 2004-12-03 2009-05-12 Medtrain Technologies, Llc Nuclear targeting sequence
US7498177B2 (en) 2006-04-24 2009-03-03 Jesus Martinez De La Fuente Quantum dots and their uses
WO2008011120A2 (en) 2006-07-21 2008-01-24 The Regents Of The University Of California Human endogenous retrovirus polypeptide compositions and methods of use thereof
US20100196492A1 (en) 2007-03-08 2010-08-05 Green Jordan J Electrostatic coating of particles for drug delivery
EP2599791A1 (en) * 2007-04-27 2013-06-05 Genentech, Inc. Potent, stable and non-immunosuppressive anti-CD4 antibodies
EP2187971A2 (en) 2007-08-01 2010-05-26 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services A fold-back diabody diphtheria toxin immunotoxin and methods of use
WO2009054996A2 (en) 2007-10-25 2009-04-30 Genelux Corporation Systems and methods for viral therapy
EP2130912A1 (en) 2008-06-04 2009-12-09 Institut für Viruskrankeiten und Immunprophylaxe Pestivirus replicons providing an RNA-based viral vector system
US9333163B2 (en) 2008-10-06 2016-05-10 Massachusetts Institute Of Technology Particles with multiple functionalized surface domains
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US20120192298A1 (en) 2009-07-24 2012-07-26 Sigma Aldrich Co. Llc Method for genome editing
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
US20110229556A1 (en) 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
EP2603450B1 (en) 2010-08-14 2016-11-02 University of Massachusetts Yeast cell wall particle for receptor-targeted nanoparticle delivery
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2012093258A2 (en) 2011-01-05 2012-07-12 Imperial Innovations Limited Treatment and screening
CN102851304A (zh) 2011-06-30 2013-01-02 复旦大学 基于静电包衣的三元非病毒核酸递释系统及其制备方法
KR102480188B1 (ko) 2012-09-14 2022-12-21 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Mhc ii형 제한된 mage-a3을 인식하는 t 세포 수용체
WO2014068079A1 (en) 2012-11-01 2014-05-08 Max-Delbrück-Centrum für Molekulare Medizin An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
JP2016511747A (ja) * 2013-01-04 2016-04-21 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子表面結合に基づく薬物の組織への送達
EP2943565B1 (en) * 2013-01-14 2018-03-28 Fred Hutchinson Cancer Research Center Compositions and methods for delivery of immune cells to treat un-resectable or non-resected tumor cells and tumor relapse
GB201302427D0 (en) 2013-02-12 2013-03-27 Midatech Ltd Nanoparticle delivery compositions
EP2970985A1 (en) * 2013-03-14 2016-01-20 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9828582B2 (en) 2013-03-19 2017-11-28 Duke University Compositions and methods for the induction and tuning of gene expression
EP3783098A1 (en) 2013-05-14 2021-02-24 Board Of Regents, The University Of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
ES2716867T3 (es) 2013-05-31 2019-06-17 Cellectis Sa Endonucleasa de asentamiento LAGLIDADG que escinde el gen de receptor de células T alfa y usos de la misma
EP3049116B1 (en) 2013-09-23 2019-01-02 Rensselaer Polytechnic Institute Nanoparticle-mediated gene delivery, genomic editing and ligand-targeted modification in various cell populations
JP6506749B2 (ja) 2013-10-22 2019-04-24 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド フェニルケトン尿症のためのmRNA療法
CN105873952A (zh) 2013-10-31 2016-08-17 弗莱德哈钦森癌症研究中心 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
BR112017001183A2 (pt) 2014-07-21 2017-11-28 Novartis Ag tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado
ES2841274T3 (es) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res Inmunoterapia con células T específica para WT-1
US20160176969A1 (en) 2014-11-26 2016-06-23 Xencor, Inc. Heterodimeric antibodies including binding to cd8
EA035817B1 (ru) 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2017112944A1 (en) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
JP2019508037A (ja) 2016-02-16 2019-03-28 イェール ユニバーシティーYale Universit 標的化遺伝子編集を増強するための組成物およびその使用方法
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP4711465A2 (en) 2016-04-14 2026-03-18 Fred Hutchinson Cancer Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
EP3458104A1 (en) 2016-05-18 2019-03-27 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
CA3040533A1 (en) 2016-12-02 2018-06-07 Cartesian Therapeutics, Inc. Cancer immunotherapy with highly enriched cd8+ chimeric antigen receptor t cells
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경
CN112055695A (zh) 2018-05-01 2020-12-08 弗莱德哈钦森癌症研究中心 用于基因表达的纳米粒子和其用途

Similar Documents

Publication Publication Date Title
JP2020504133A5 (https=)
JP6854530B2 (ja) 病原体ワクチンならびにその製造および使用方法
JP7564842B2 (ja) がんの治療のためのmica/bアルファ3ドメインによるワクチン接種
JP2021001191A (ja) フィロウイルスコンセンサス抗原、核酸構築物、およびそれから作製されるワクチン、ならびにその使用方法
JP2008530245A5 (https=)
JP2010166921A5 (https=)
JP2011520783A5 (https=)
IL260030B2 (en) Therapeutic anticancer neoepitope vaccine
CN102448491A (zh) 疫苗组合物和其使用方法
JP2004121263A (ja) 子宮頸がんの治療
JP2017513502A (ja) 組み換え型リステリアワクチン株およびこれを生産する方法
EP2694534B1 (en) Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
AU2017211387A1 (en) Personalized delivery vector-based immunotherapy and uses thereof
JP2019506175A5 (https=)
EA029470B1 (ru) Способ стимулирования формирования защитного иммунитета против норовируса
Whitlock et al. Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge
CN1548537B (zh) 疫苗制备方法和抗肿瘤疫苗
KR20250044945A (ko) 기존의 미생물 면역을 활용한 암 치료
Verma et al. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB
KR20180064158A (ko) 구제역 바이러스의 가용성 다가 항원단백질 및 이의 용도
Zhang et al. A Milestone in the Shift from “Passive Killing” to “Active Immunomodulation” in Cancer Treatment—Progress in Melanoma Vaccine Research
EP3077820B1 (en) Proteins and nucleic acids useful in vaccines targeting staphylococcus aureus
WO2017177910A1 (zh) 增强抗肿瘤免疫反应的新型免疫策略和免疫组合物
Zhang et al. A comprehensive investigation of Glycoprotein-based nucleic acid vaccines for Hantaan Virus
ES2807173T3 (es) Inmunógenos de anticuerpos ampliamente neutralizantes del VIH-1, métodos de generación y usos de los mismos